Venetoclax‐based non‐intensive induction followed by allogenic stem‐cell transplantation in elderly acute myeloid leukemia patients with adverse cytogenetics
European Journal of Haematology · 2024
DOI: 10.1111/ejh.14290 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Haematology, 2024. Verfasst von Amel Soua und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Institut Paoli-Calmettes, INSERM UMR 1068, CNRS UMR725, CNRS, Aix-Marseille University, Marseille, France. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Bridged Bicyclo Compounds, Heterocyclic, Hematopoietic Stem Cell Transplantation, Sulfonamides. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Introduction
Elderly acute myeloid leukemia (AML) patients with poor‐risk cytogenetics have a poor outcome with intensive chemotherapy (IC). While Venetoclax (VEN) has changed the outcomes of elderly unfit patients treatment, it is unknown whether it could be effective in poor‐risk cytogenetics 60–75 years old patients. Materials and Methods We included 60–75‐year‐old AML patients eligible to allogenic stem cell transplantation (allo‐SCT) treated with VEN (combined with azacitidine or with Cladribin and Aracytine) at Institut Paoli Calmettes, between 2020 and 2023 and compared this cohort with patients treated by IC between 2010 and 2019.
Results
Twenty six patients were treated with VEN (17 in combination with azacitidine and 9 with Cladribin and Aracytine) and 90 were treated with IC. Thirteen patients (50%) had a TP53 mutation. The median time for leucocyte and platelet counts recovery was 26 days (range 0–103) and 26 days (range, 0–63). The median duration of the first hospitalization was 32 days (ranges, 7–79). The composite response rate was 69% (CR = 50%, CRi = 4%, MLFS = 15%). Allo‐SCT could be performed in 42% of cases. Median overall survival (OS) was 7.9 months (20.9 months in the group of patients who transitioned to allo‐SCT). We found no difference with the historical cohort of patients treated with IC except a trend toward less lower and upper tract gastro‐intestinal (GI) tract infections in the VEN group (respectively 8% vs 26%, p = .06; and 0% vs. 13% p = .06).
Conclusion
VEN‐based treatment was found to be effective in high risk AML can be considered as an alternative to IC in patients aged 60–75 with adverse cytogenetics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Institut Paoli-Calmettes, INSERM UMR 1068, CNRS UMR725, CNRS, Aix-Marseille University, Marseille, France.
- Department of Biostatistics, Institut Paoli-Calmettes, Marseille, France.
- Department of Biopathology, Institut Paoli-Calmettes, Marseille, France.
- Department of Cancer Biology, Institut Paoli-Calmettes, Marseille, France.
Zitieren
APA
Soua, A., Gilhodes, J., Iat, A., Hicheri, Y., Saillard, C., Rouzaud, C., D'Incan, E., Rey, J., Mohty, B., Charbonnier, A., Ittel, A., Alary, A. S., Gelsi-Boyer, V., Murati, A., Lhoumeau, A. C., Devillier, R., Boher, J. M., Mozziconacci, M. J., Vey, N., …, & Garciaz, S. (2024). Venetoclax‐based non‐intensive induction followed by allogenic stem‐cell transplantation in elderly acute myeloid leukemia patients with adverse cytogenetics. European Journal of Haematology. https://doi.org/10.1111/ejh.14290
Vancouver
Soua A, Gilhodes J, Iat A, Hicheri Y, Saillard C, Rouzaud C, et al. Venetoclax‐based non‐intensive induction followed by allogenic stem‐cell transplantation in elderly acute myeloid leukemia patients with adverse cytogenetics. European Journal of Haematology. 2024. doi:10.1111/ejh.14290
BibTeX
@article{Soua2024,
author = {Soua, Amel and Gilhodes, Julia and Iat, Alexandre and Hicheri, Yosr and Saillard, Colombe and Rouzaud, Camille and D'Incan, Evelyne and Rey, Jérôme and Mohty, Bilal and Charbonnier, Aude and Ittel, Antoine and Alary, Anne-Sophie and Gelsi-Boyer, Véronique and Murati, Anne and Lhoumeau, Anne-Catherine and Devillier, Raynier and Boher, Jean-Marie and Mozziconacci, Marie-Joelle and Vey, Norbert and Hospital, Marie-Anne and Garciaz, Sylvain},
title = {Venetoclax‐based non‐intensive induction followed by allogenic stem‐cell transplantation in elderly acute myeloid leukemia patients with adverse cytogenetics},
journal = {European Journal of Haematology},
year = {2024},
doi = {10.1111/ejh.14290}
}
EUVIMED